Last checked at 6 Apr 2020 07:00
6 April 2020 |
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces the following PDMR share transactions.
As part of the Company's Deferred Share Bonus Plan (DSB), executive directors and employees can sacrifice part of their annual bonus to be invested in the DSB, which for every share purchased on behalf of the employee they receive matching shares which are deferred for a minimum of three years. As a result of no executive bonuses being awarded for the financial year ended 31 December 2019, Chris Meredith (CEO) and Eddie Johnson (CFO) have elected to sell certain existing shares to use the proceeds to re-invest in the DSB. The decision to participate in the DSB was taken on 24 March 2020.
The Company was notified on 1 April 2020 that following his decision to participate on 24 March, Chris Meredith, who is a Director and PDMR, executed the exercise of 11,427 Ordinary Shares of 5p from the existing DSB and subsequently sold 19,993 Ordinary Shares of 5p each on 1 April 2020 at a share price of 258.026p per Ordinary Share. The proceeds from the sale of the shares will be entirely used to purchase shares in the DSB which administratively occurs in May 2020, and will increase Chris Meredith's beneficial interest in the Company from the level prior to these transactions.
As a result of these transactions Chris Meredith's beneficial interest in the Company is as follows, prior to the purchase of DSB shares in May 2020:
Deferred Share Bonus Plan (DSB)
PDMR | No. of DSBs prior to exercise | DSBs exercised | Ordinary Shares sold | Ordinary Shares retained | DSBs after exercise |
Chris Meredith | 38,983 | 11,427 | 11,427 | Nil | 27,556 |
Overall Holding
PDMR | Holding prior to exercise | Number of shares exercised | Dividend Shares received | Number of shares sold | Sale price (p) | Resultant holding | % of issued share capital |
Chris Meredith | 1,503,377 | 11,427 | 0 | 19,993 | 258.026p | 1,494,811 | 0.7% |
The Company was notified on 1 April 2020 that following his decision to participate on 24 March, Eddie Johnson, who is a Director and PDMR, executed the exercise of 11,688 options from the existing Deferred Annual Bonus Plan (DAB). Eddie Johnson elected to receive an additional 218 dividend shares which were earned during the holding period under the terms of the DAB. Eddie Johnson has also executed the exercise of 2,023 Ordinary Shares of 5p from the existing DSB and subsequently sold 15,952 Ordinary Shares of 5p each on 1 April 2020 at a share price of 258.026p per Ordinary Share. The proceeds from the sale of the shares will be used to purchase shares in the DSB which administratively occurs in May 2020, and will increase Eddie Johnson's beneficial interest in the Company from the level prior to these transactions.
As a result of these transactions Eddie Johnson's beneficial interest in the Company is as follows, prior to the purchase of shares in May 2020:
Deferred Share Bonus Plan (DSB)
PDMR | No. of DSBs prior to exercise | DSBs exercised | Ordinary Shares sold | Ordinary Shares retained | DSBs after exercise |
Eddie Johnson | 73,247 | 2,023 | 2,023 | Nil | 71,224 |
Deferred Annual Bonus Plan (DAB)
PDMR | DABs prior to exercise | DABs exercised | Dividend Shares received | Ordinary Shares sold | Ordinary Shares retained | DABs after exercise |
Eddie Johnson | 22,542 | 11,688 | 218 | 11,906 | Nil | 10,854 |
Overall Holding
PDMR | Holding prior to exercise | Number of shares exercised | Dividend Shares received | Number of shares sold | Sale price (p) | Resultant holding | % of issued share capital |
Eddie Johnson | 59,426 | 13,711 | 218 | 15,952 | 258.026p | 57,403 | 0.027% |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Chris Meredith | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Exercise of 11,427 shares from the Deferred Share Bonus Plan · Sale of 19,993 Ordinary Shares of 5p | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 19,993 Aggregated price: £2.58026 | ||||
e) | Date of the transaction: 01/04/2020 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Eddie Johnson | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transaction: · Exercise of 11,688 shares from the Deferred Annual Bonus Plan · Award of 218 Dividend Shares from the Deferred Annual Bonus Plan · Exercise of 2,023 shares from the Deferred Share Bonus Plan · Sale of 15,952 Ordinary Shares of 5p | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 15,952 Aggregated price: £2.58026 | ||||
e) | Date of the transaction: 01/04/2020 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
-End -
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer | |
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
Mary-Jane Elliott / Matthew Neal / Philippa Gardner / Rosie Phillips | AMS@consilium-comms.com |
Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
Daniel Adams / Gary Clarence / Patrick Robb |
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBand® Fix8TM. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com.